Revance Therapeutics reported $28.37M in Sales Revenues for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Sales Change
Abbvie ABBV:US $ 14583M 1045M
Aerie Pharmaceuticals AERI:US $ 33.31M 3.48M
ALKERMES ALKS:US $ 276.22M 2.33M
Bristol Myers Squibb BMY:US $ 11887M 239M
Cara Therapeutics CARA:US $ 23M 18.21M
Coherus Biosciences CHRS:US $ 60.15M 0.04M
Eli Lilly And LLY:US $ 6488M 1322M
Endo International Ordinary Shares ENDP:US $ 569.11M 83.14M
Horizon Pharma HZNP:US $ 876.41M 8.83M
JAZZ PHA JAZZ:US $ 932.88M 119.16M
Johnson & Johnson JNJ:US $ 24020M 594M
Merk MRK:US $ 14593M 1308M
Neurocrine Biosciences NBIX:US $ 378.2M 67.6M
Pacira Pharmaceuticals PCRX:US $ 169.41M 11.42M
Procter & Gamble PG:US $ 19515M 134M
Revance Therapeutics RVNC:US $ 28.37M 3.11M
Supernus Pharmaceuticals SUPN:US $ 170.05M 17.55M
Teva Pharmaceutical Industries TEVA:US $ 3786M 125M